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Abstract
Background: Cross-talk between deregulated signaling pathways in cancer cells causes uncontrolled growth and
proliferation. These cancers cells become more aggressive and quickly develop resistance to therapy. Therefore
targeting of these deregulated pathways simultaneously can result in efficient cell death of cancer cells. In this
study we investigated co-expression of Cox-2 and FoxM1 in a cohort of colorectal carcinoma (CRC) samples and
also examined whether inhibition of Cox-2 and FoxM1 simultaneously can lead to inhibition of cell viability and
induction of apoptosis in colorectal cancer cell lines and in vivo xenografts.
Methods: Protein expression of Cox-2 and FoxM1 was determined in a large cohort of 770 clinical CRC samples in
a tissue micro-array format by immunohistochemistry. Cell death was measured using live dead assay. Apoptosis
was measured by annexin V/PI dual staining. Immunoblotting was performed to examine the expression of proteins.
Calcusyn software was utilized to estimate the synergistic doses using chou and Talalay method.
Results: Co-expression of Cox-2 and FoxM1 was detected in 33.3 % (232/697) of CRC’s and associated with an
aggressive phenotype characterized by younger age (p = 0.0191), high proliferative index marker; Ki-67 (p = 0.004)
and MMP-9 (p = 0.0116) as well as activation of AKT (p = 0.0214). In vitro, inhibition of FoxM1 and Cox-2 with
pharmacological inhibitors; Thiostrepton and NS398 resulted in efficient down-regulation of FoxM1 and Cox-2
expression along with in-activation of AKT and inhibition of colony formation, invasion and migratory capability of
CRC cells. In addition, there was also inhibition of cell viability and induction of apoptosis via the mitochondrial
apoptotic pathway in CRC cell lines. Finally, treatment of CRC xenograft tumors in nude mice with combination of
Cox-2 and FoxM1 inhibitors inhibited tumor growth significantly via down-regulation of Cox-2 and FoxM1 expression.
Conclusions: These findings demonstrate that co-expression of Cox-2 and FoxM1 might play a critical role in the
pathogenesis of CRC. Therefore, targeting of these pathways simultaneously with sub toxic doses of pharmacological
inhibitors can be a potential therapeutic approach for the treatment of this subset of CRC.
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Background
Despite increased awareness in the general population re-
garding colorectal cancer (CRC), it still remains a major
cause of mortality and morbidity worldwide [1]. This in-
crease has been attributed to a combination of environ-
mental and genetic factors in the general population [2, 3].
Even though CRC is very well studied along with estab-
lished diagnostic markers, most of CRC cancers present at
late stages of disease and therefore have a poor prognosis
[4]. In addition, recurrence and metastasis of CRC also
carry a very high mortality rate [5]. Therefore, there is a
need for improvement in the diagnosis of CRC as well as
identification of newer therapeutic targets that can be
specifically drugged to improve the management of these
cancers.
An important key survival molecule that is currently
being investigated as a molecular marker and a potential
therapeutic target is cyclooxygenase-2 (Cox-2) in various
cancers. The main function of Cox is to synthesize pros-
taglandins from arachidonic acid [6]. There are two iso-
forms of Cox; Cox-1 that is found to be expressed in
normal cells [7] and Cox-2 that is preferentially expressed
in cancer cells [7] and its expression is enhanced by pro-
inflammatory cytokines and carcinogens [8, 9]. Cox-2 has
been found to be over-expressed by us and others in a var-
iety of cancer including breast, ovary, colorectal, thyroid
and lung [10–14]. Prophylactic use of Cox-2 inhibitors
such as aspirin has been shown to decrease the incidence
of certain cancers [15–18].
Forkhead box protein M1 (FoxM1) is a member of
FoxM family that consists of more than 50 proteins that
are characterized by a conserved 100 amino acid DNA
binding domain [19, 20]. FoxM1 has also been known to
regulate the transcriptional activity of number of genes in-
cluding cyclin B, cyclin A and Aurora B kinase, which are
very important for cell cycle progression and mitotic entry
[21–23]. Loss of FoxM1 expression has also been reported
to generate mitotic spindle defects leading to mitotic catas-
trophe [21, 24, 25]. FoxM1 signaling has been implicated
to be associated with carcinogenesis of tumor development
in CRC as well as other solid tumors [22, 26–33].
A number of dysregulated survival pathways have the
ability to cross-talk with each other to increase aggres-
siveness of various cancers [34, 35]. These cross-talks
allow the cancer cell to avoid different in vivo and in
vitro threats thereby allowing un-supervised growth and
proliferation and the cancers cells become more aggres-
sive and quickly develop resistance to therapy [35].
Inhibiting one pathway may not be enough to elicit a
complete response because of the cross-talk with other
pathways thereby eliciting a feedback response to reacti-
vate the targeted pathway [36]. Targeting multiple path-
ways also helps in decreasing drug-induced toxicity by
using sub-toxic doses in combination.
There have been many studies performed to investi-
gate the role of Cox-2 and FoxM1 in tumorigenesis in-
dependently however there are only few studies where
these molecules are studied together [37]. Therefore, in
this study, we first investigated co-expression of Cox-2
and FoxM1 in CRC clinical samples followed by deter-
mining whether targeting of co-expression of FoM1 and
Cox-2 can generate efficient anticancer effects in CRC
cells both in vitro as well as in vivo models.
Results
Evaluation of molecular expression of Cox-2 and FoxM1
in CRC tissues
Immunohistochemical analysis of Cox-2 expression was
interpretable in 726 CRC spots and the incidence of
Cox-2 over-expression was found to be 60.6 % (440/
726). FoxM1 expression was interpretable in 719 CRC
spots and the incidence of FoxM1 over-expression was
found to be 50.3 % (362/719). Cox-2 was seen predomin-
antly in cytoplasmic compartment and FoxM1 expression
was seen predominantly in the nuclear compartment. Co-
expression of Cox-2 and FoxM1 was seen in 33.3 % (232/
697) of cases and were significantly associated with each
other (p = 0.0115). Co-expression of Cox-2 and FoxM1
were found to be significantly associated with clinical pa-
rameters such as younger age (p = 0.0191) and mucinous
histology (p = 0.0174) but were not associated with sex, or
American Joint Committee on Cancer (AJCC) stage.
Molecular association of this co-expression was seen
with proliferative marker Ki-67 (p = 0.0004), p-AKT (p =
0.0214) and MMP-9 (p = 0.0116) (Table 1). No survival
difference was seen between patients showing Cox-2 and
FoxM1 co-expression and those with normal or reduced
expression (p = 0.4796) (Table 1 and Additional file 1:
Figure S1).
Inhibition of Cox-2 and FoxM1 causes inhibition of cell
viability in CRC cell lines
In vitro, we initially sought to determine expression of
Cox-2 and FoxM1 in a panel of CRC cell lines by
immuno-blotting. We found that out of five CRC cell lines,
only HT29 and Caco-2 had constitutive co-expression of
Cox-2 and FoxM1 (Fig. 1a) therefore we selected these two
cell lines in our study. We next determined the effect of
Cox-2 inhibitor NS398 and FoxM1 inhibitor Thiostrepton
[38] that has also been shown to possess proteasomal in-
hibition activity [39] on the expression of these proteins.
At first, Caco-2 and HT29 cells were treated with 50 and
100 μM NS398 for 48 h. NS398 treatment failed to down-
regulate the expression of FoxM1 in both the cell lines,
even though, expression of Cox-2 was down-regulated and
there was inactivation of AKT (Fig. 1b). This data was fur-
ther confirmed by transfecting HT29 cells with specific
siRNA targeted against Cox-2. As shown in Fig. 1c, similar
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results were obtained where there was no effect on the ex-
pression of FoxM1 in CRC cell lines while the expression
of Cox-2 decreased and there was in-activation of AKT
following transfection with siRNA targeting Cox-2. In a
separate experiment, CRC cell lines were treated with 5
and 10 μM Thiostrepton for 48 h and immunoblotted with
FoxM1, Cox-2, p-AKT and total AKT antibodies. The
doses of Thiostrepton used have been previously shown to
down-regulate expression of FoxM1 in other tumor cell
lines without any off target effect or toxicity to normal
peripheral blood mononuclear cells (PBMNC) [40, 41]. As
shown in Fig. 1d, Thiostrepton treatment down-regulated
expression of FoxM1 and Cox-2 and caused dephosphory-
lation of AKT at 10 μM in both the cell lines. Similar re-
sults were obtained when CRC cell lines were transfected
with siRNA targeted against FoxM1 for 48 h and immuno-
blotted with antibodies against FoxM1, Cox-2, p-AKT and
total AKT (Fig.1e). These data suggest that FoxM1 is
expressing upstream of Cox-2 and there is a link between
FoxM1 and Cox-2 in CRC cells. Finally, we sought to
Table 1 Correlation of Cox-2 & Fox-M1 co-expression with clinico-pathological parameters in colorectal carcinomaa
Total Both high Any-1-low p value
Number Percent Number Percent Number Percent
Total number of cases 697 232 33.3 465 66.7
Age
≤50 years 229 32.9 90 39.3 139 60.7 0.0191
>50 years 468 67.1 142 30.3 326 69.7
Sex
Male 358 51.4 116 32.4 242 67.6 0.6111
Female 339 48.6 116 34.2 223 65.8
Tumour Site
Left colon 548 82.3 176 32.1 372 67.9 0.5821
Right colon 118 17.7 41 34.8 77 65.2
Histological Type
Adenocarcinoma 628 90.1 200 31.9 428 68.1 0.0174
Mucinous Carcinoma 69 9.9 32 46.4 37 53.6
Tumour Stage
I 80 12.2 25 31.3 55 68.7 0.4160
II 233 35.4 75 32.2 158 67.8
III 266 40.4 98 36.8 168 63.2
IV 79 12.0 22 27.8 57 72.2
Differentiation
Well 66 9.5 21 31.8 45 68.2 0.3709
Moderate 549 78.8 178 32.4 371 67.6
Poor 82 11.8 33 40.2 49 59.8
Ki-67
High 590 87.7 209 35.4 381 64.6 0.0004
Low 83 12.3 14 16.9 69 83.1
p-AKT
High 454 72.3 169 37.2 285 62.8 0.0214
Low 174 27.7 48 27.6 126 72.4
MMP-9
High 342 52.2 129 37.7 213 62.3 0.0116
Low 313 47.8 89 28.4 224 71.6
Survival
OS 5 Years 73.6 68.5 0.4796
aData were not available for (Tumor Site NA = 31), (Tumor Stage NA = 39), (Ki-67 NA = 24), (p-AKT NA = 69) and (MMP-9 NA = 42)
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Fig. 1 NS398 and Thiostrepton inhibits cell viability in CRC cell lines (a) HT29, DLD1, Caco-2, HCT-15 and LOVO cells were lysed and immuno-blotted
with Cox-2, FoxM1 and Beta-actin antibodies (b) Caco-2 and HT29 cell lines were treated with 50 and 100 μM NS398 for 48 h. Proteins were lysed and
immunoblotted with antibodies against FoxM1, Cox-2, p-AKT, total AKT and Beta-actin. c HT29 cells were either transfected with 50 and 100nM siRNA,
specific against Cox-2 or scrambled siRNA for 48 h. Cells were lysed and equal amounts of proteins were immuno-blotted with antibodies against
FoxM1, Cox-2, p-AKT, total AKT and Beta-actin. d Caco-2 and HT29 cell lines were treated with 5 and 10 μM Thiostrepton for 48 h. Proteins were lysed
and immunoblotted with antibodies against FoxM1, Cox-2, p-AKT, total AKT and Beta-actin. e HT29 cells were either transfected with 50 and 100nM
siRNA, specific against FoxM1 or scrambled siRNA for 48 h. Cells were lysed and equal amounts of proteins were immuno-blotted with antibodies
against FoxM1, Cox-2, p-AKT, total AKT and beta-actin. f Caco-2 and HT29 cell lines were incubated with 0-100 μM NS398 for 48 h. Cell viability was
measured by MTT assays as described in Materials and Methods. The graph displays the mean +/- SD (standard deviation) of three independent
experiments, *p < 0.05, statistically significant (Students t-test). g Caco-2 and HT29 cell lines were incubated with 0-25 μM Thiostrepton for 48 h.
Cell viability was measured by MTT assays as described in Materials and Methods. The graph displays the mean +/- SD (standard deviation) of three
independent experiments, *p < 0.05, statistically significant (Students t-test)
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determine whether treatment of CRC cell lines with Cox-2
and FoxM1 inhibitors leads to inhibition of cell viability.
Caco-2 and HT29 were cultured in the presence of 1, 10,
25, 50 and 100 μM NS398 for 48 h and cell viability was
assayed using MTT assay. As shown in Fig. 1f, there was a
dose dependent inhibition of cell viability in both the cell
lines that reached significance at 50 μM for Caco-2 and
25 μM for HT29 respectively (p < 0.05). Interestingly, this
response was not seen in Cox-2 deficient DLD1 and
LOVO cells up to doses of 100 μM NS398 (Additional file
2: Figure S2 and Additional file 3: Figure S3). Similarly, the
two cell lines were cultured in the presence of 0.5, 1, 5, 10
and 25 μM Thiostrepton for 48 h. Data revealed that there
was also a dose dependent response to Thiostrepton treat-
ment that reached statistical significance at 10 μM for
HT29 and Caco-2 cell lines respectively (Fig. 1b). In
addition, there was partial response in FoxM1 negative
cell line; LOVO as shown in Additional file 3: Figure
S3. These data suggest that targeting Cox-2 and FoxM1
using specific inhibitors led to inhibition of cell viability
in CRC cells.
Synergistic activity of thiostrepton and NS398 in CRC cell
lines
As our data showed FoxM1 and Cox-2 co-expression
was present in CRC, we hypothesized that targeting of
FoxM1 and Cox-2 expression together can lead to effi-
cient cytotoxic effects in CRC cells. Therefore we sought
to determine whether co-treatment of CRC cell lines
with Thiostrepton, and NS398 at sub-toxic doses, can
potentiate anticancer effects in CRC cells.
We conducted multiple experiments to determine the
optimal doses that could be used in combination to in-
hibit cell viability, migration and colony formation and
induce apoptosis in CRC cell lines. Using Chou and
Talalay method [42], we found that 5 μM Thiostrepton
and 10uM NS398 in combination exerted maximum
synergistic apoptotic response in HT29 and Caco-2 cells
with combination index of 0.286 and 0.332 respectively
(Fig. 2, Additional file 4: Table S1, Additional file 5:
Table S2). Therefore, we first treated CRC cells with sub-
optimal doses of Thiostrepton (5 μM) and NS398 (10 μM)
for various time points and found that the optimal syner-
gistic response was detected at 48 h following treatment
(Additional file 6: Figure S4). Therefore, we treated Caco-
2 and HT29 cells with combination of NS398 and Thios-
trepton for 48 h and assessed the cell viability by MTT
assay. As shown in Fig. 3a, neither Thiostrepton nor
NS398 alone could inhibit cell viability, however, co-
treatment with Thiostrepton and NS398 led to significant
inhibition of cell viability in CRC cells (p < 0.01). Next, we
determined whether combination of Thiostrepton and
Fig. 2 Calculation of optimal doses required for co-treatment of CRC cells by Thiostrepton and NS398. HT29 and Caco-2 cells were treated with
0.5, 1.0, 5.0, 10 and 25 μM Thiostrepton or 1.0, 10, 25, 50 and 100 μM NS398 alone or in different combinations to calculate the Synergistic apoptotic
response of Thiostrepton and NS398 for 48 h and dose effect (a and c) and Fractional effect (b and d) graphs were generated using Calcusyn
software. Apoptotic response analysis was done as mean ± SD values normalized to control. Combination indices were calculated using Chou
and Talalay methodology
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NS398 could inhibit colony formation in CRC cells. As
shown in Fig. 3b, there was significant inhibition in colony
formation in HT29 cells as compared to treatment alone.
Combination of Thiostrepton and NS398 also inhibited
cell invasion and migration in HT29 cells as compared to
treatment alone (Fig. 3c). We finally investigated whether
co-treatment of CRC cells with sub-optimal doses of
Thiostrepton and NS398 could inhibit expression of
FoxM1, Cox-2 and MMP-9 by immunoblotting. As
shown in Fig. 3d, combination treatment of Thiostrep-
ton and NS398 successfully down-regulated expression
of FoxM1, Cox-2 and MMP-9 and inactivated p-AKT
without disrupting the expression of total AKT in Caco-2
and HT29 cell lines. These data indicate that co-treatment
with Thiostrepton and NS398 synergistically inhibits cell
viability and migratory properties of CRC cells. Finally,
Cox-2 deficient cell line; DLD1 cells and Cox-2 and
FoxM1 deficient cell line; LOVO did not show any syner-
gistic response when treated with combination of 5 μM
Thiostrepton and 10 μM NS398 and the cell inhibition
detected were due to Thiostrepton treatment alone
(Additional file 7: Table S3 and Additional file 8: Table
S4) confirming specificity of NS398 and Thiostrepton
treatment against Cox-2 and FoxM1expression.
Fig. 3 Combination of NS398 and Thiostrepton at sub-optimal doses inhibits cell viability and decreases cell invasion/migration capability of CRC
cells. a Caco-2 and HT29 cell lines were incubated with either 10 μM NS398 or 5 μM Thiostrepton alone or in combination for 48 h. Cell viability
was measured by MTT assays as described in Materials and Methods. The graph displays the mean +/- SD (standard deviation) of three independent
experiments, *p < 0.05, statistically significant (Students t-test). b Colony formation assays were performed as described in Materials and Methods. HT29
cells were treated with either 10 μM NS398 or 5 μM Thiostrepton alone or in combination for 48 h. Subsequently, cells were plated on Soft agar plates
for 4 weeks. After 4 weeks, plates were stained and manually counted. Bar graph denotes number of colonies counted manually. c HT29 cells were
treated with 10 μM NS398 and 5 μM Thiostrepton alone or in combination for 48 h. Following treatment, Invasion-Migration assay were performed as
described in the material and methods section. d Caco-2 and HT29 cell lines were treated with 10 μM NS398 and 5 μM Thiostrepton either alone or in
combination for 48 h. Proteins were lysed and immunoblotted with antibodies against FoxM1, Cox-2, p-AKT, total AKT, MMP-9 and Beta-actin
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Co-treatment of CRC cells with thiostrepton and NS398
induces apoptosis via mitochondrial apoptotic pathway
For efficient apoptosis to occur, the mitochondrial apop-
totic pathway needs to be activated. Bax, a pro-apoptotic
BH3 domain only protein of the Bcl-2 family [43] is the
first protein that undergoes conformational changes for
the mitochondrial apoptotic pathway to be activated [44].
To investigate the effect of co-treatment with Thiostrepton
and NS398 on activation of the mitochondrial pathway,
we treated HT29 cells for various time periods and exam-
ined the conformational changes in Bax protein by
immuno-precipitation. As shown in Fig. 4a, conformation-
ally changed Bax was detected after 2 h, peaked within
16 h and then decreased at 24 h of treatment with 5 μM
Thiostrepton and 10 μM NS398. Once Bax is conforma-
tionally changed, it causes changes in the mitochondrial
membrane potential. To investigate this, we treated Caco-
2 and HT29 cells with either Thiostrepton or NS398 alone
or in combination for 48 h and examined the change in
mitochondrial membrane potential by flow cytometry.
Neither Thiostrepton nor NS398 could affect the mito-
chondrial membrane potential alone however when com-
bination of both inhibitors were used together, there was
an increase in cells undergoing mitochondrial membrane
damage as depicted by green bars (Fig. 4b). Once there are
changes in the mitochondrial membrane potential, there is
release of cytochrome into the cytosole (Data not shown)
leading to activation and cleavage of downstream caspases.
To determine this, we treated HT29 cells with NS398
(10 μM), Thiostrepton (5 μM) and a combination of the
two for 48 h and examined cleavage of caspase-9, caspase-
3 and PARP by immunoblotting. Caspase-9, -3 and PARP
were cleaved in cells that were treated with combination of
Thiostrepton and NS398 (Fig. 4c). Once the downstream
caspases are activated and cleaved, it leads to cell death via
apoptosis. To confirm this, we visualized cells under an
Olympus fluorescent microscope using a longpass filter
after 48 h treatment with NS398, Thiostrepton or a com-
bination of two inhibitors after staining them with 50 μM
calcein AM and 8 μM ethidium homodimer. As shown in
Fig. 4d, there were more green stained cells depicting live
cells in samples treated with Thiostrepton or NS398 alone.
The cells stained red representing dead cells in sample that
was treated with combination of Thiostrepton and NS398.
Apoptosis was further confirmed by annexinV/PI dual
staining that was investigated by flow cytometry. These set
of data confirm that combination of Thiostrepton and
NS398 treatment induces apoptosis in CRC cells via acti-
vation of mitochondrial apoptotic pathway.
Inhibition HT29 xenografts by combinational treatment of
thiostrepton and NS398 in nude mice
The synergistic effect of the combination of Thiostrepton
and NS398 in vitro suggested that this combination would
likely to be effective in tumor xenografts in vivo. There-
fore, we sought to determine whether co-treatment of
Thiostrepton with NS398 potentiated the inhibition of
CRC cell line generated xenograft tumor in nude mice.
For xenograft study, mice were inoculated subcutaneously
into the right abdominal quadrant with10 million HT29
cells in 200 μl PBS. After 1 week of inoculation, mice
were randomly assigned into four groups: The first
group received DMSO as control vehicle while the other
three groups received NS398 (15 mg/kg), Thiostrepton
(150 mg/kg) and combination of 15 mg/kg NS398 and
150 mg/kg Thiostrepton, injected twice weekly, intraperi-
toneally respectively. After 5 weeks treatment, mice were
sacrificed and tumors were collected. As shown in Fig. 5a,
there was significant regression of tumor volume at the
end of second week in the group of animal treated with
Thiostrepton and NS398. Neither Thiostrepton nor NS398
alone resulted in significant inhibition of xenograft tumors.
A significant reduction in tumor weight (Fig. 5b) was also
observed in mice treated with Thiostrepton and NS398
(p < 001). We also visualized images of the tumor, post-
necropsy and found that there was significant shrinkage in
the size of the tumor following treatment with combin-
ation of Thiostrepton and NS398 as compared to treat-
ment alone (Fig. 5c). Finally, we analyzed the status
FoxM1, Cox-2, p-AKT, total AKT and caspase-3 in HT29
xenograft at the end of study. As shown in Fig. 5d, the
level of FoxM1, Cox-2, MMP-9 and caspase-3 were re-
markably deceased along with in-activation of AKT in tu-
mors of mice co-treated with Thiostrepton and NS398,
compared to vehicle, Thiostrepton and NS398 alone treat-
ment. Our data indicates that co-treatment with Thios-
trepton and NS398 augmented antitumor effects in HT29
cell xenografts in Nude mice.
Discussion
In this study, we have investigated the role of Cox-2 and
FoxM1 co-expression in a large cohort of 770 Middle
Eastern CRC in a tissue microarray format to determine
the protein expression by immunohistochemistry. It has
been previously shown that Cox-2 and FoxM1 expression
are associated with a poor prognosis in CRC [45, 46]. In
this study, we found a significant association between
FoxM1 and Cox-2 over-expression in Middle Eastern
CRC samples (p = 0.0115). Co-expression of FoxM1 and
Cox-2 was also found to be associated with an aggressive
phenotype that was characterized by younger age (p =
0.0191), proliferative marker Ki-67 (0.0004), MMP-9 (p =
0.0116) and activation of AKT (p = 0.0214). These data
reiterates the point that targeting these two molecules
simultaneously using small molecular inhibitors may be
more beneficial for the management of this aggressive
phenotype of CRC when compared to treatment with sin-
gle agent.
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Cross talk between survival pathways is slowly emer-
ging as one of the leading causes of drug resistance to
small molecular inhibitors for the treatment of cancer.
After an initial response to the treatment, resistance to
therapy quickly develops due to re-activation of the
target molecule either by up-stream pro-survival path-
way molecules or negative feed-back mechanism by
down-stream molecules. To counteract this resistance, re-
cent studies have shown targeting multiple pro-survival
molecules of different survival pathways that are associated
Fig. 4 Combination of NS398 and Thiostrepton at sub-optimal doses induces caspase-dependent apoptosis via the mitochondrial pathway in
CRC cells. a HT29 cells were treated with combination of 10 μM NS398 and 5 μM Thiostrepton for indicated time periods. Cells were lysed in 1 %
Chaps lysis buffer and subjected to immuno-precipitation with anti-Bax 6A7 monoclonal antibody and probed with specific polyclonal anti-Bax
antibody for detection of conformationally changed Bax protein. In addition, the total cell lysates were applied directly to SDS–PAGE, transferred
to immobilon membrane and immuno-blotted with specific anti-Bax polyclonal antibody. b Caco-2 and HT29 cells were treated with 10 μM
NS398 and 5 μM Thiostrepton either alone or in combination for 48 h. Live cells with intact mitochondrial membrane potential (red bars) and
dead cells with lost mitochondrial membrane potential (green bars) was measured by JC-1 staining and analyzed by flow cytometry as described
in Materials and Methods. The graph displays the mean +/- SD (standard deviation) of three independent experiments. c HT29 cells were treated
with 10 μM NS398 and 5 μM Thiostrepton alone or in combination for 48 h. Cells were lysed and equal amounts of proteins were immunoblotted
with antibodies against caspase-9, caspase-3, cleaved caspase-3, PARP, and Beta-actin. d Caco2 and HT29 cells were treated with 10 μM NS398
and 5 μM Thiostrepton either alone or in combination for 48 h and cell death was analyzed by Live/Dead Assay. e HT29 cells were treated with
10 μM NS398 and 5 μM Thiostrepton alone or in combination for 48 h. Thereafter, the cells were washed, and stained with annexin V/propidium
iodide, and analyzed by flow cytometry as described in Materials and methods
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with each other with combination of specific inhibitors
simultaneously is more beneficial than treatment with sin-
gle agent alone [47, 48]. Combination treatment is also
beneficial because the dose of each drug is considerably
decreased when used in combination thereby reducing the
chances of toxicity to normal cells. Therefore, the role of
single agent treatment with molecular inhibitors is dimin-
ishing and targeting various cancers with multiple inhibi-
tors is on the rise.
A strong association between expression of FoxM1
and Cox-2 with MMP-9 expression has been reported in
a number of cancers [31, 49, 50]. Previously, it has also
been reported in lung cancer that transcriptional depletion
of FoxM1 expression can cause reduced Cox-2 expression
and on the other hand, induced over-expression of FoxM1
protein can increase Cox-2 promoter activity [37]. These
findings are in conco rdance with our data where pharma-
cological and transcriptional inhibition of FoxM1 expres-
sion down-regulates the expression of Cox-2. Furthermore,
our data also demonstrates that depletion of Cox-2 ex-
pression does not affect FoxM1 expression suggesting
that FoxM1 is functional upstream of Cox-2. Combined
Fig. 5 Combination of NS398 and Thiostrepton at sub-optimal inhibits growth of HT29 xenograft and down-regulates expression of Cox-2, FoxM1
and p-AKT. Nude mice at 6 weeks of age were injected with 10 million HT29 cells. a The volume of each tumor was measured every week. The
average (n = 6) tumor volumes in vehicle-treated mice () and mice treated with indicated doses of NS398 (15 mg/kg ), Thiostrepton (150 mg/kg )
and a combination of NS398 and Thiostrepton (NS398 15 mg/kg + Thiostrepton 150 mg/kg; ) were plotted. The results are expressed as mean ±
SD (n = 6). *P <0.001 compared with vehicle-treated mice. b After 5 weeks of treatment, mice were sacrificed and tumor weights were measured.
The results are expressed as mean ± SD. *P < 0.001 compared with vehicle-treated mice by Student t test. c Representative tumor images of
vehicle-treated mice and mice treated with NS398, Thiostrepton and combination of both agents after necropsy. d Whole cell homogenates from
mice treated with vehicle, 15 mg/kg NS398, 150 mg/kg Thiostrepton and a combination of 15 mg/kg NS398, + 150 mg/kg Thiostrepton were
immuno -blotted with FoxM1, Cox-2, p-AKT, total AKT, MMP-9, caspase-3, and Beta-actin antibodies
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targeting of Cox-2 and FoxM1 with pharmacological
inhibitors also depletes colony formation as well as in-
vasive and migratory capabilities of CRC cells in vitro
via down-regulation of MMP-9 thereby indicating the
utility of combined targeting of these molecules for in-
hibition of metastasis in CRC cells.
Combined targeting of Cox-2 and FoxM1 not only in-
hibits the invasive and migratory capability of CRC cells,
they also cause inhibition of cell viability and induction
of apoptosis. This effect occurs via inactivation of an im-
portant survival molecule; p-AKT, that plays an import-
ant role in the survival of cancer cells and is found to be
constitutively activated in various cancers [51]. Our data
showed that dephosphorylation of AKT led to activation
of the mitochondrial apoptotic pathway initiated by Bax
conformational changes and translocation to the mito-
chondrial membrane, thereby leading to changes in the
mitochondrial membrane potential and finally activation
and cleavage of caspases. Once caspases are activated,
there is cleavage of PARP; an essential enzyme that is re-
quired for repairing single stranded breaks in DNA [49]
and is a hallmark of cells undergoing apoptosis. Our in
vivo studies further validate our hypothesis that co-
treatment of mice bearing palpable CRC xenograft with
Thiostrepton and NS398 leads to regression of tumor
growth via down-regulation of FoxM1, Cox-2, MMP-9,
inactivation of AKT and cleavage of caspase-3 which is
consistent with our in vitro findings.
Conclusions
Altogether, we found that 33.3 % of CRC clinical sam-
ples co-express Cox-2 and FoxM1 and this sub-group is
associated with an aggressive phenotype. Therefore, our
data highlights the importance of co-targeting of deregu-
lated survival pathways (Cox-2 and FoxM1) in CRC cells
can lead to anticancer effects. Our data showed that
combination treatment of CRC cells with sub-optimal
doses of Thiostrepton and NS398 caused functional inhib-
ition of Cox-2 and FoxM1 simultaneously. Even though,
Thiostrepton and NS398 have been previously shown to
be effective in suppressing growth and inducing apoptosis
in CRC cells at higher concentrations [31, 52], this study
emphasizes the importance of targeting multiple survival
molecules with sub-optimal doses of Thiostrepton and
NS398 to successfully inhibit cell growth, invasion, migra-
tion and induce apoptosis in CRC. Further studies are
warranted to further investigate the utility of combination
treatment with Thiostrepton and NS398 for the treatment
of CRC in clinical settings.
Material and methods
Patient selection and tissue microarray construction
Seven hundred and seventy patients with CRC diagnosed
between 1990 and 2011 were selected from King Faisal
Specialist Hospital and Research Centre. Clinical and
histopathological data were available for all these pa-
tients. Colorectal Unit, Department of Surgery, provided
long-term follow-up data. Patients with colon cancer
underwent surgical colonic resection and rectal cancer
underwent anterior resection or abdominoperineal re-
section. Majority of node positive colon cancers received
5-fluorouracil based adjuvant chemotherapy. A vast ma-
jority of the rectal cancers received radiotherapy alone
or chemo-radiotherapy prior to surgery followed by adju-
vant chemotherapy after surgery. Tissue microarrays were
constructed from formalin-fixed, paraffin-embedded colo-
rectal carcinoma specimens as described previously [53].
Institutional Review Board (IRB) of the King Faisal Spe-
cialist Hospital & Research Centre approved the study
(NSTIP 10-BIO-959-20 and RAC 2140 005).
Immunohistochemistry (IHC)
TMA slides were processed and stained manually as
described previously [54]. Sections were deparaffinized
in xylene and rehydrated through graded alcohol to
water. Antigen retrieval was done in a Pascal Pressure
cooker at 120 °C for 8 min using the Dako Retrieval so-
lution, pH 6 (S2369; Dako Cytomation, Copenhagen,
Denmark). Endogenous peroxidase activity was blocked
by incubating the slides in 3 % H2O2 in water for
30 min at room temperature. Sections were incubated
in 1 % BSA for 30 min then wiped off and dilution of
Cox-2 and FoxM1 was applied on the slides and incu-
bated overnight at room temperature. Subsequently
sections were incubated with Envision + secondary anti-
body for 1 h at room temperature and visualization was
done using the liquid DAB + substrate chromogen sys-
tem. Only fresh cut slides were stained simultaneously
to minimize the influence of slide ageing and maximize
repeatability and reproducibility of the experiment. De-
tails of primary antibodies used, dilutions, cut-off and
incidences of positive cases are listed in Additional file
9: Table S5. H-score was used for categorizing the ex-
pression of Cox-2 and FoxM1. Each TMA spot was
assigned an intensity score from 0 to 3 (I0, I1–I3) and
proportion of the tumor staining for that intensity was
recorded in 5 % increments from 0 to 100 (P0, P1–P3).
A final H score (range, 0–300) was obtained by adding
the sum of scores obtained for each intensity I and pro-
portion of area stained. X-tile plots were constructed
for assessment of biomarker and optimization of cutoff
points based on outcome, as described previously [55].
The CRCs were stratified into two groups based on X-tile
plots: one with complete absence or reduced staining and
the other with overexpression. For Ki-67 cut-off of ≥50 %
nuclear staining was used and for p-AKT intensity
score 2+/3+ was considered as positive.
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Statistical analysis
Contingency table analysis and χ2 tests were used to
study relationship between clinicopathological variables
and gene amplification. The limit of significance for all
analyses was defined as a P value of 0.05; two-sided tests
were used in all calculations. The JMP 10.0 software
package (SAS Institute, Cary, NC) was used for data
analyses.
Reagents and antibodies
Thiostrepton (FoxM1 selective inhibitor) [56] was pur-
chased from Tocris Cookson Inc (Ellisville, MO). NS398
(COX-2 inhibitor) was purchased from Caymen chemical
company, (Ann Arbor, MI). Antibodies against cleaved
caspase-3, Cox-2, AKT and p-AKT antibodies were pur-
chased from Cell Signaling Technologies (Beverly, MA).
FoxM1, Bax, Beta-actin, caspase-3 and poly (ADP) ribose
polymerase (PARP) antibodies were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). MMP-9 anti-
bodies were purchased from Anespec, (San Jose, CA).
Annexin V/PI kit was purchased from Molecular Probes
(Eugene, OR, USA).
Cell culture
HT29, DLD1, LOVO, HCT-15 and Caco-2 were ob-
tained from Deutsche Sammlung von Mikroorganismen
und Zellkulturen (DSMZ), Braunschweig, Germany. All
cell lines were tested for immunological markers and
cytogenetics. The cell lines were also fingerprinted and
species was confirmed by IEF of AST, MDH and NP.
Cells were cultured in RPMI 1640 medium supple-
mented with 10 % (vol/vol) fetal bovine serum, 100 U/
ml Penicillin and 100 U/ml Streptomycin at 37 °C in hu-
midified atmosphere containing 5 % CO2. All the experi-
ments were performed in RPMI-1640 containing 5 %
fetal bovine serum.
Cell growth studies by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays
104 cells were incubated in triplicate in a 96-well plate in a
final volume of 0.2 ml for 48 h at 37 °C. Cell viability assay
using MTT was performed as described previously [57].
Live dead assay
To determine cell death, Live-Dead assay (Invitrogen,
Eugene, OR) was used as described by the manufacturer.
HT29 and Caco-2 cells were treated either alone with
NS398, and Thiostrepton or in combination as described
in the legends. Following incubation for 48 h, cells were
suspended in 1 ml PBS containing 50 mM calcein AM
and 8 mM ethidium homodimer and cells were incu-
bated in the dark for 20 min. 50 μl of suspension was
transferred on slides and visualized under an Olympus
fluorescent microscope using a longpass filter.
Soft agar colony assay
Soft agar colony experiments were performed according
to the manufacturer’s protocol (Cheminon International,
Temecula, CA, USA). Briefly, after treatment of cells
with NS398, Thiostrepton or a combination of the two
inhibitors for 48 h, 2500 cells were plated in 0.5 ml cul-
ture medium containing 0.4 % (v/v) top agar and 20 %
fetal bovine serum (FBS) layered over a basal layer of
0.8 % (v/v) agar and 20 % FBS with culture medium and
allowed to grow for 4 weeks as described previously (our
REF). Following 4 weeks incubation, cells were stained
at a final concentration of 1 mg/ml cell stain solution
that was supplied with the kit.
Cell invasion and migration assay
Cell invasion and migration assay were performed using
24-well Transwell Permeable Supports with 8-lM pores
(Corning, Lowell, MA). Briefly, after treatment of cells
with NS398, Thiostrepton or a combination of the two
inhibitors for 48 h, cells were harvested, counted again
and 1.25 x 105 cells were suspended in serum-free
medium and seeded into Transwell inserts either un-
coated (for migration assay) or coated (for invasion
assay) with growth factor-reduced Matrigel (BD Biosci-
ences, Bedford, MA). Bottom wells were filled with
complete media for 24 h. After incubation of 24 h, filters
containing the cells were stained with Diff-Quick stain set
(Fisher Scientific, Pittsburg, PA), photographed under a
fluorescent microscope and manual cell counts were ob-
tained [41].
Gene Silencing using siRNA
FoxM1 siRNA, Cox-2 siRNA and Scrambled control
siRNA were purchased from Qiagen (Valencia, CA, USA).
Cells were transfected using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA) for 6 h following which the lipid and
siRNA complex was removed and fresh growth medium
was added. Cells were lysed 48 h after transfection and
specific protein levels were determined by Western Blot
analysis with specific antibodies.
Annexin V/PI dual staining
HT29 and Caco-2 cells were treated either with NS398,
Thiostrepton or in combination as described in the leg-
ends. For detection of apoptosis, cells were harvested
and percentage apoptosis was measured by flow cytome-
try after staining with flourescein-conjugated annexin-V
and propidium iodide (PI) (Molecular probes, Eugene,
OR) [58].
Measurement of mitochondrial membrane potential
Cells were treated with NS398 and Thiostrepton as de-
scribed in the legends for 48 h, washed twice with PBS,
and re-suspended in mitochondrial incubation buffer.
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JC1 staining and flow cytometry were done as described
previously.
Cell lysis and immunoblotting
Cells were lysed as previously described [44]. Proteins
were immunoblotted with different antibodies and visu-
alized by the enhanced chemiluminescence (Amersham,
Piscataway, NJ) method.
Detection of Bax conformational changes
Detection of Bax conformation was performed as previ-
ously described [44]. In brief, HT29 cells were treated with
combination of 10 μM NS398 and 5 μM Thiostrepton for
indicated time periods after which proteins were lysed and
immunoblotted using N20 Bax polyclonal antibody.
Animals and xenograft study
Six weeks old nude mice were obtained from Jackson La-
boratories (Maine, USA) and maintained in a pathogen
free animal facility at least 1 week before use. All animal
studies were done in accordance with institutional guide-
lines. For Xenograft study, mice were inoculated sub-
cutaneously into the right abdominal quadrant with
10x106 cells of HT29 in 200 μL PBS. After 1 week, mice
were randomly assigned into four groups: The first group
received DMSO. The three groups received N398 (15 mg/
kg), Thiostrepton (150 mg/kg) and combination of 15 mg/
kg NS398 and 150 mg/kg Thiostrepton, intra-peritoneally
respectively. Mice were given these drugs twice weekly.
The body weight and tumor volume of each mouse was
monitored weekly. The tumor volume was measured as
described previously [31]. After 5 weeks treatment, mice
were sacrificed and individual tumors were weighed, then
snap-frozen in liquid nitrogen for storage.
Additional files
Additional file 1: Figure S1. Kaplan-Meier survival curve of CRC cases
showing co-expression of Cox-2 and FoxM1 as compared to cases with
normal or reduced expression (p = 0.4796).
Additional file 2: Figure S2. DLD1 cells were incubated with 0-100 μM
NS398 for 48 h. Cell viability was measured by MTT assays as described in
Materials and Methods. The graph displays the mean +/- SD (standard
deviation) of three independent experiments, *p < 0.05, statistically
significant (Students t-test).
Additional file 3: Figure S3. LOVO cells were incubated with 0-100 μM
NS398, 0-25 μM Thiostrepton or a combination of both drugs for 48 h. Cell
viability was measured by MTT assays as described in Materials and Methods.
The graph displays the mean +/- SD (standard deviation) of three
independent experiments, *p < 0.05, statistically significant (Students t-test).
Additional file 4: Table S1. Combination Index calculation using Chou
and Talalay method in Caco-2 cell line.
Additional file 5: Table S2. Combination Index calculation using Chou
and Talalay method in HT29 cell line.
Additional file 6: Figure S4. (A and B) Caco-2 (A) and HT29 (B) cells
were incubated with either 10 μM NS398, 5 μM Thiostrepton or a
combination of both drugs for indicated time points. Cell viability was
measured by MTT assays as described in Materials and Methods. The
graph displays the mean +/- SD (standard deviation) of three independent
experiments, *p < 0.05, statistically significant (Students t-test).
Additional file 7: Table S3. Combination Index calculation using Chou
and Talalay method in DLD1 cell line.
Additional file 8: Table S4. Combination Index calculation using Chou
and Talalay method in LOVO cell line.
Additional file 9: Table S5. Details of primary antibodies used in the
study.
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